Monocyclic Heteroaryl compounds
AssigneeARIAD Pharmaceuticals, Inc.
InventorsWilliam C. Shakespeare, Wei-Sheng Huang, David C. Dalgarno, Xiaotian Zhu, R. Mathew Thomas, Yihan Wang, Jiwei Qi, Rajeswari Sundaramoorthi, Dong Zou, Chester A. Metcalf, III, Tomi K. Sawyer, Jan Antoinette C. Romero
Life of this patent
Estimating the term…
Abstract
This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
Claims28
A compound of the Formula:
- or a tautomer or a pharmaceutically acceptable salt thereof, wherein:
- Ring T represents
- Ring A represents a 5- or 6-membered aryl or heteroaryl ring;
- Ring B represents a 5- or 6-membered aryl or heteroaryl ring;
- L1 is NR1C(O) or C(O)NR1;
- each Ra and Rt is independently selected from halo, —CN, —NO2, —R4, —OR2, —NR2R3, —C(O)YR2, —OC(O)YR2, —NR2C(O)YR2, —SC(O)YR2, —NR2C(═S)YR2, —OC(═S)YR2, —C(═S)YR2, —YC(═NR3)YR2, —YP(═O)(YR4)(YR4), —Si(R4)3, —NR2SO2R2, —S(O)rR2, —SO2NR2R3 and —NR2SO2NR2R3, wherein Y is independently a bond, —O—, —S— or —NR3—;
- each R1, R2 and R3 is independently selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocycle and heteroaryl, and in addition, NR2R3 may be a 5- or 6-membered saturated, partially saturated or unsaturated ring, which is optionally substituted and contains 0-2 additional heteroatoms selected from N, O and S(O)r;
- each R4 is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic and heteroaryl;
- Rb is selected from halo, —CN, —NO2, —R4, —OR2, —NR2R3, —C(O)YR2, —OC(O)YR2, —NR2C(O)YR2, —SC(O)YR2, —NR2C(═S)YR2, —OC(═S)YR2, —C(═S)YR2, —YC(═NR3)YR2, —YP(═O)(YR4)(YR4), —Si(R4)3, —NR2SO2R2, —S(O)rR2, —SO2NR2R3, and —NR2SO2NR2R3, Ring C, and —L2-Ring D, wherein Y is independently a bond, —O—, —S— or —NR3—;
- in which:
- (i) Ring C is a 5- or 6-membered heteroaryl or heterocyclic ring comprising carbon atoms and 1-3 heteroatoms independently selected from O, N and S(O)r and which is optionally substituted with 1 to 5 substituents, Rc;
- (ii) L2 is (CH2)z, O(CH2)x, NR3(CH2)x, S(CH2)x, and (CH2)xNR3C(O)(CH2)x, oriented in either direction;
- and,
- (iii) Ring D is a 5- or 6-membered heterocyclic or heteroaryl ring comprising carbon atoms and 1-3 heteroatoms independently selected from O, N and S(O)r and which is optionally substituted with 1 to 5 Rd substituents;
- each Rc and Rd is independently halo, ═O, ═S, —CN, —NO2, —R4, —OR2, —NR2R3, —Si(R4)3, —C(O)YR2, —OC(O)YR2, —NR2C(O)YR2, —SC(O)YR2, —NR2C(═S)YR2, —OC(═S)YR2, —C(═S)YR2, —YC(═NR3)YR2, —YP(═O)(YR4)2, —NR2SO2R2, —S(O)rR2, —SO2NR2R3 or —NR2SO2NR2R3;
- each of the foregoing alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic and heteroaryl moieties is optionally substituted;
- m is 0, 1, 2, 3 or 4;
- n is 0, 1, 2 or 3;
- p is 1, 2, 3, 4 or 5;
- r is 0, 1 or 2;
- x is 0, 1, 2 or 3;
- z is 1, 2, 3 or 4;
- each optional substituent for an unsaturated carbon atom of an aryl or heteroaryl moiety and for a carbon atom of an alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, cycloalkyl, cycloalkenyl, cycloalkynyl or non-aromatic heterocyclic group is selected from F, Cl, Br, I, —CN, —R4, —OR2, —S(O)rR2, —SO2NR2R3, —NR2R3, —(CO)YR2, —O(CO)YR2, —NR2(CO)YR2, —S(CO)YR2, —NR2C(═S)YR2, —OC(═S)YR2, —C(═S)YR2, —YC(═NR3)Y′R2, —COCOR2, —COMCOR2, —YP(═O)(YR4)(YR4), —Si(R2)3, —NO2, —NR2SO2R2 and —NR2SO2NR2R3, where M is a 1-6 carbon alkyl group;
- each optional substituent for an alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, cycloalkyl, cycloalkenyl, cycloalkynyl or non-aromatic heterocyclic group alternatively is selected from ═O, ═S, ═NH, ═NNR2R3, ═NNHC(O)R2, ═NNHCO2R2, and ═NNHSO2R2;
- and
- each optional substituent on a nitrogen is selected from R4, —NR2R3, —C(═O)R2, —C(═O)OR2, —C(═O)SR2, —C(═O)NR2R3, —C(═NR2)NR2R3, —C(═NR2)OR2, —C(═NR2)R3, —COCOR2, —COMCOR2, —CN, —SO2R3, S(O)R3, —P(═O)(YR2)(YR2), —NR2SO2R3 and —NR2SO2NR2R3.
A compound selected from the following:
- or a pharmaceutically acceptable salt thereof.
A compound selected from the following:
- 1-Methyl-5-(2-methyl-5-[4-(4-methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenylcarbamoyl]-phenylethynyl)-1H-imidazole-2-carboxylic acid amide,
- 1-Methyl-5-(2-methyl-5-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenylcarbamoyl]-phenylethynyl)-1H-imidazole-2-carboxylic acid amide,
- 5-[5-(3-Imidazol-1-yl-5-trifluoromethylphenylcarbamoyl)-2-methyl-phenylethynyl]-1-methyl-1H-imidazole-2-carboxylic acid amide,
- N-{3-chloro-4-[(4-methylpiperazin-1-yl)methyl]phenyl}-4-methyl-3-[(1-methyl-1H-imidazol-5-yl)ethynyl]benzamide,
- 1-methyl-5-({2-methyl-5-[({4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}carbonyl)amino]phenyl}ethynyl)-1H-imidazole-2-carboxamide, and
- 5-[(5-{[4-{[(3R)-3-(dimethylamino)pyrrolidin-1-yl]methyl}-3-(trifluoromethyl)phenyl]carbamoyl}-2-methylphenyl)ethynyl]-1-methyl-1H-imidazole-2-carboxamide,
- or a pharmaceutically acceptable salt thereof.
The compound 1-Methyl-5-(2-methyl-5-[4-(4-methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenylcarbamoyl]-phenylethynyl)-1H-imidazole-2-carboxylic acid amide or a pharmaceutically acceptable salt thereof.
The compound 1-Methyl-5-(2-methyl-5-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenylcarbamoyl]-phenylethynyl)-1H-imidazole-2-carboxylic acid amide or a pharmaceutically acceptable salt thereof.
The compound 5-[5-(3-Imidazol-1-yl-5-trifluoromethylphenylcarbamoyl)-2-methyl-phenylethynyl]-1-methyl-1H-imidazole-2-carboxylic acid amide or a pharmaceutically acceptable salt thereof.
The compound N-{3-chloro-4-[(4-methylpiperazin-1-yl)methyl]phenyl}-4-methyl-3-[(1-methyl-1H-imidazol-5-yl)ethynyl]benzamide or a pharmaceutically acceptable salt thereof.
The compound 1-methyl-5-({2-methyl-5-[({4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}carbonyl)amino]phenyl}ethynyl)-1H-imidazole-2-carboxamide or a pharmaceutically acceptable salt thereof.
The compound 5-[(5-{[4-{[(3R)-3-(dimethylamino)pyrrolidin-1-yl]methyl}-3-(trifluoromethyl)phenyl]carbamoyl}-2-methylphenyl)ethynyl]-1-methyl-1H-imidazole-2-carboxamide or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.